Interní Med. 2006; 8(9): 393-395

Some notes about treatment of dyslipidemia

MUDr. Michal Vrablík Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Treatment of dyslipidemia has become a corner stone of intervention of the patients with increased cardiovascular risk. There are complex recommendations for dietary and physical activity changes without which the therapeutic success cannot be achieved. We have several types of hypolipidemic drugs (statins, fibrates, resins, ezetimibe, niacin). Other compounds can also be used in modification of plasma lipid levels (antiobezitics, some antidiabetics, estrogens). When side effects of the treatment occur it is necessary to test the tolerance of another drug of the same class or achieve better control of the metabolic disorder with a combination of hypolipidemic drugs.

Keywords: Key words: dyslipidemia, statins, fibrates, resins, ezetimibe, niacin, diet, physical activity.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Some notes about treatment of dyslipidemia. Interní Med. 2006;8(9):393-395.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005 Aug; 258 (2): 94-114. Go to original source... Go to PubMed...
    2. Cífková R a členové pracovní skupiny. Prevence kardiovaskulárních onemocnění v dospělém věku. Cor Vasa 2005, 47 (9 Suppl): 3-14.
    3. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet. 2005 Nov 26; 366 (9500): 1829-1831. Go to original source... Go to PubMed...
    4. Cuff D, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich J. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diab Care 2003, 26: 2977-2982. Go to original source... Go to PubMed...
    5. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005 Jan 5; 293 (1): 43-53. Go to original source... Go to PubMed...
    6. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre E, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).Proc Natl Acad Sci U S A. 2005 Jun 7; 102 (23): 8132-8137. Go to original source... Go to PubMed...
    7. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005 Dec 12-26; 165 (22): 2671-2676. Go to original source... Go to PubMed...
    8. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26; 366 (9500): 1849-1861. Go to original source... Go to PubMed...
    9. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91: 2596-2604. Go to original source... Go to PubMed...
    10. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7; 346 (6): 393-403. Go to original source... Go to PubMed...
    11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 2003; 326: 1423-1430. Go to original source... Go to PubMed...
    12. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?Curr Opin Lipidol. 2003 Dec; 14 (6): 575-583. Go to original source... Go to PubMed...
    13. Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005 May; 21 (5): 665-682. Go to original source... Go to PubMed...
    14. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev. 2005 Spring; 23 (1): 15-30. Go to original source... Go to PubMed...
    15. Štulc T, Vrablík M, Králíková E. Zásady diagnostiky a léčby hyperlipoproteinemií. Medicína po promoci 2004, 5 (3): 68-73.
    16. Vrablík M, Češka R, Bretšnajdrová A, Nejedlá G, Vrablíková K. Dieta při hyperlipoproteinemii. DMEV 1999; 3: 143-147.
    17. Vrablík M, Štulc T, Králíková E, Kvasilová M, Procházková R. Statiny, fibráty a jejich kombinace v léčbě hyperlipoproteinémií. Medicína po promoci 2004, 5 (4): 53-59.
    18. Widimsky J Sr. Studie FIELD prezentovaná a publikovaná. Nepřesvědčivé výsledky terapie fenofibrátem u pacientů s diabetes mellitus. Vnitr Lek. 2006 Jan; 52 (1): 80-84. Go to PubMed...
    19. Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin Cardiol. 2006 Feb; 29 (2): 52-55. Go to original source... Go to PubMed...
    20. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, Brown BG. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004 Feb 1; 93 (3): 307-312. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.